CT125A

CT125A is a first-in-class chimeric antigen receptor T cell (CAR-T) therapy developed for the treatment of relapsed or refractory CD5-positive hematologic malignancies, including both T cell and certain B cell cancers. The therapy uses gene editing technology (CRISPR/Cas9) to knock out the endogenous CD5 gene in T cells, preventing self-activation and fratricide during CAR-T manufacturing. This enables the production of potent anti-CD5 CAR-T cells that can persist in vivo and target malignant cells expressing CD5. The CAR construct leverages fully human heavy-chain-only binding domains specific for CD5. Preclinical studies have shown safety and clinical activity in patients with relapsed/refractory CD5+ acute lymphoblastic leukemia (T-ALL), T-cell non-Hodgkin lymphoma (T-NHL), as well as certain B-cell malignancies such as mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). CT125A is currently being evaluated in early phase clinical trials[1][2][3][4][5].